PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).

Rahul R AggarwalGlenn HellerDavid W Hillman Han Xiao Joel PicusMary-Ellen TaplinTanya Barauskas Dorff Leonard J ApplemanDouglas WecksteinAkash Patnaik Alan H Bryce Daniel Shevrin James L MohlerDaniel AndersonArpit Rao Scott T TagawaAlan TanSusan Halabi Katharine E DooleyPatrick O'BrienRonald C ChenCharles J RyanScott E Eggener Michael J Morrisnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.

Keyphrases

phase iii
open label
prostate cancer
clinical trial
phase ii
radical prostatectomy
phase ii study
acute myeloid leukemia
acute lymphoblastic leukemia
study protocol
double blind
diffuse large b cell lymphoma
squamous cell carcinoma
randomized controlled trial
smoking cessation